bims-glumda Biomed News
on CGM data in management of diabetes
Issue of 2026–11–22
twenty-one papers selected by
Mott Given



  1. Case Rep Endocrinol. 2026 ;2026 1901927
      Continuous glucose monitoring (CGM) provides real-time interstitial glucose data and may detect glycemic excursions missed by point-of-care blood glucose (POC BG) testing. Inpatient evidence remains limited, especially in patients with severe dermatologic disease limiting POC access. We report a 22-year-old male with poorly controlled type 1 diabetes and Castleman disease who presented with diffuse pruritic hyperpigmented lesions, mucositis, and nail dystrophy, precluding reliable fingerstick monitoring. During his several-month hospitalization, he received high-dose corticosteroids, rituximab, and intravenous immunoglobulin, with marked glycemic variability due to steroid-induced hyperglycemia, variable intake, and intermittent refusal of care. A Dexcom G7 CGM was initiated to facilitate glucose monitoring, and a single earlobe capillary glucose measurement was obtained at the time of CGM initiation as a reference blood glucose value. CGM data were manually integrated into the electronic medical record (EMR) by nursing staff and used to support insulin titration. Most serum and POC BG measurements did not show major differences from corresponding CGM values. During the first month, time in range (TIR) was 30%, time below range was 2%, and glucose management indicator (GMI) was 8.9%. CGM was used for nearly 3 months during hospitalization, facilitating CGM when POC testing was challenging. The patient later developed respiratory failure, likely due to bronchiolitis obliterans, and died. CGM enabled continuous monitoring when fingersticks were not feasible, supporting insulin adjustment in complex inpatient hyperglycemia. Implementation requires multidisciplinary coordination and validation protocols.
    Keywords:  Castleman disease; care report; continuous glucose monitoring; type 1 diabetes
    DOI:  https://doi.org/10.1155/crie/1901927
  2. BMC Pregnancy Childbirth. 2026 Aug 20. pii: 1338. [Epub ahead of print]26(1):
       BACKGROUND: Early-onset type 2 diabetes (EOT2D), meaning type 2 diabetes diagnosed before the age of 40 disproportionately affects women from socially deprived and minority ethnic groups. EOT2D is now the most common form of pre-existing diabetes complicating pregnancy. These pregnancies carry high risks of congenital anomalies, stillbirth, neonatal death, and of both maternal and neonatal morbidity. Maternal glycaemia is the key modifiable risk factor yet remains suboptimal and is often accompanied by limited self-monitoring of blood glucose (SMBG). Continuous Glucose Monitoring (CGM) offers continuous real-time glucose profiles, potentially enabling better dietary, lifestyle and therapy adjustments.
    METHODS / DESIGN: The PROTECT trial is a multicentre, randomised controlled trial designed to evaluate whether CGM improves maternal glucose and neonatal outcomes in women with EOT2D. The trial will recruit 422 pregnant participants (≤ 16 weeks 0 days' gestation, HbA1c ≥ 43 mmol/mol) from around 20 UK NHS antenatal diabetes clinics. After a run-in phase with masked CGM, participants will be randomised to either real-time CGM (FreeStyle Libre 3) or standard SMBG. The primary maternal outcome is percentage of time in pregnancy-specific glucose target range (3.5-7.8 mmol/L). The primary neonatal outcome is a composite of neonatal care unit admission or death. Secondary outcomes include maternal HbA1c, glycaemic variability, insulin use, obstetric complications, neonatal morbidity, psychosocial measures, and cost-effectiveness. An internal pilot will assess recruitment feasibility, before proceeding to the full trial. Qualitative interviews with women and healthcare professionals will explore barriers and facilitators to CGM use. Statistical analyses will follow intention-to-treat principles.
    DISCUSSION: This is the largest trial to date investigating CGM in EOT2D pregnancy, aiming to generate robust evidence on clinical efficacy, lived experiences, and economic impact, informing future NHS policy and practice.
    TRIAL REGISTRATION: ISRCTN12804317 Registration Date: 23/10/2023.
    Keywords:  Continuous glucose monitoring; Pregnancy; Randomised controlled trial; Technology; Type 2 diabetes
    DOI:  https://doi.org/10.1186/s12884-026-09469-4
  3. Diabetologia. 2026 Nov 14.
      Prediabetes is a clinically useful but biologically heterogeneous risk state defined by episodic laboratory thresholds that identify overlapping rather than identical populations. Continuous glucose monitoring can reveal temporal glycaemic variation that fasting plasma glucose, OGTT and HbA1c cannot capture. Recent evidence indicates that sensor-derived metrics distinguish conventionally defined prediabetes from normoglycaemia and can stratify future glycaemic risk, making eventual incorporation into classification scientifically plausible. The case for immediate diagnostic use, however, is not established. Continuous glucose monitoring measures interstitial rather than venous plasma glucose; device performance and sampling duration influence the derived metrics; and treatment-oriented glucose targets were not developed as diagnostic cut-offs in people without diabetes. Before a continuous glucose monitoring phenotype can be incorporated into the definition of prediabetes, it should demonstrate reproducibility over time and across devices, provide clinically meaningful information beyond established tests and risk factors, change a management decision and show a favourable downstream balance between benefit and harm. Until these conditions are met, continuous glucose monitoring is better positioned as an instrument for phenotyping and risk stratification than as an independent diagnostic criterion.
    Keywords:  Continuous glucose monitoring; Diagnostic criteria; Dysglycaemia; Prediabetes; Risk stratification
    DOI:  https://doi.org/10.1007/s00125-026-06925-w
  4. Endocrinol Diabetes Nutr (Engl Ed). 2026 Nov 20. pii: S2530-0180(26)00201-5. [Epub ahead of print] 501829
      In people with type 2 diabetes mellitus (T2DM) on basal insulin therapy, with or without other antihyperglycemic agents, suboptimal glycemic control increases the risk of hyperglycemia and hypoglycemia, which can negatively impact patients' clinical outcomes and quality of life. Continuous glucose monitoring (CGM) has been shown to improve glycemic control by reducing HbA1c and increasing time in range, without increasing hypoglycemic events. It also represents a cost-effective intervention in the analyzed models. This document presents the consensus recommendations of the Spanish Diabetes Society (SED), the Spanish Society of Endocrinology and Nutrition (SEEN), the Spanish Society of Primary Care Physicians (SEMERGEN), the Spanish Society of Family and Community Medicine (SEMFyC), and the Spanish Society of General and Family Physicians (SEMG) on the priority indications for the use of CGM in this population, glycemic control targets, follow-up, and discontinuation criteria.
    Keywords:  Basal insulin; Continuous glucose monitoring; Control glucémico; Diabetes; Diabetes tipo 2; Glycemic control; Insulina basal; Monitorización continua de glucosa; Type 2 diabetes
    DOI:  https://doi.org/10.1016/j.endien.2026.501829
  5. Diabetes Obes Metab. 2026 Nov 16.
       AIMS: To characterize metabolic heterogeneity in Type 2 diabetes mellitus (T2DM), we used continuous glucose monitoring (CGM) data to identify nocturnal glucose patterns and examine their associations with clinical and metabolic characteristics and microvascular complications.
    MATERIALS AND METHODS: This cross-sectional study analysed CGM data from 3218 patients with T2DM at a single centre (training set, n = 2214; validation set, n = 1004). We first identified nocturnal glucose patterns using k-means clustering based on glucose dynamic features (GDF). After excluding subtypes dominated by high or low glucose levels, we baseline-corrected the remaining nocturnal glucose curves, extracted morphological features and repeated clustering. We then compared clinical characteristics and the prevalence of diabetic retinopathy (DR) and diabetic kidney disease (DKD) across subtypes, and evaluated reproducibility in the validation set.
    RESULTS: GDF-based clustering identified five nocturnal glucose patterns that differed in CGM metrics, β-cell function and insulin resistance indices (all p < 0.001). Baseline-corrected clustering identified stable, declining and rising relative trajectories. Compared with stable trajectories, rising trajectories were associated with prevalent DR (OR = 1.38, 95% CI: 1.04-1.82), and declining trajectories with prevalent DKD (OR = 1.28, 95% CI: 1.00-1.63) in adjusted models for the training set. These associations were reproduced in temporal internal validation, and corresponding adjusted prevalence-ratio associations remained significant after false discovery rate correction.
    CONCLUSIONS: Nocturnal glucose patterns characterize heterogeneity in metabolic profiles and prevalent microvascular complications in T2DM. Longitudinal studies are needed to clarify the temporal direction of these associations.
    Keywords:  Type 2 diabetes mellitus; cluster analysis; continuous glucose monitoring; microvascular complications; nocturnal glucose patterns
    DOI:  https://doi.org/10.1111/dom.71560
  6. Diabetes Metab J. 2026 Nov;50(6): 1044-1057
      Early dysglycemia, including prediabetes, represents heterogeneous and dynamic states that are incompletely captured by fasting plasma glucose, glycosylated hemoglobin, or a single oral glucose tolerance test. Continuous glucose monitoring (CGM) provides a higher-density assessment of glucose behavior under free-living conditions, enabling characterization of fasting, postprandial, nocturnal and activity-related glucose patterns before the onset of diabetes. This narrative review summarizes current evidence on CGM in normoglycemia towards early dysglycemia, with emphasis on conventional CGM metrics, higher-order features derived from raw glucose time series, and emerging artificial intelligence approaches. Existing studies show that individuals with prediabetes have higher mean glucose, greater time above tight glucose ranges, lower time in tight range and greater glycemic variability than normoglycemic comparators. However, absolute differences are small, and distributions overlap substantially. More recent approaches, including the concept of glucotypes, multi-feature classifiers, personalized postprandial response models, glucodensity methods and glucose foundation models, suggest that CGM may capture richer temporal and individualized phenotypes than consensus summary metrics alone, supporting future risk stratification, mechanistic subphenotyping and targeted prevention. However, model validation remains limited, and outcome-linked CGM thresholds are not yet established. At present, CGM should still be viewed as a promising research and phenotyping tool in early dysglycemia.
    Keywords:  Continuous glucose monitoring; Prediabetic state; Review
    DOI:  https://doi.org/10.4093/dmj.2026.0776
  7. Diabetes Obes Metab. 2026 Nov 15.
    FreeDM2 Study Group
       AIMS: We previously showed that FreeStyle Libre (FSL) real-time continuous glucose monitoring system (rtCGM) reduces glycated haemoglobin (HbA1c) at 16 and 32 weeks compared with capillary self-monitoring of blood glucose (SMBG) in adults with Type 2 diabetes and above target glucose levels, managed with basal insulin and SGLT-2 inhibitor and/or GLP-1 agonist therapy. We assess the cost-effectiveness of rtCGM compared with SMBG.
    MATERIALS AND METHODS: Participant-level baseline and follow-up health status (Euroqol-5-dimensions-5-levels) and within-trial healthcare resource-use data were collected. We estimated quality-adjusted life-years (QALYs) and participant-level costs at 16 and 32 weeks. Long-term cost-effectiveness from the United Kingdom National Health Service perspective was evaluated using the IQVIA CORE Diabetes Model with a 3.5% discount rate. Sensitivity analyses assessed structural and parameter uncertainty.
    RESULTS: Within-trial analyses found no significant difference at 32 weeks between rtCGM and SMBG in QALYs or healthcare costs. At 32 weeks, adjusted incremental QALYs were -0.015 (95% CI: -0.031 to 0.003) and incremental costs were £254 (95% CI: -£587 to £1070). The lifetime projected incremental QALYs were 0.730 (95% CI: 0.688-0.773) and incremental costs were £4341 (95% CI: 3558-5125), generating an incremental cost-effectiveness ratio (ICER) of £5943 per QALY. At least 4 years of maintained glycaemic benefits are required for rtCGM to be cost-effective. Sensitivity analyses were robust to the base-case results.
    CONCLUSIONS: Benefits of FSL rtCGM in lowering HbA1c in people with Type 2 diabetes on basal insulin plus SGLT-2 inhibitor and/or GLP-1 agonist therapy is likely to justify costs through improved health outcomes and reduced long-term costs of diabetes-related complications.
    Keywords:  Type 2 diabetes; basal insulin; continuous glucose monitoring; cost‐effectiveness analysis; glucose monitoring; randomised controlled trial
    DOI:  https://doi.org/10.1111/dom.71476
  8. Diabetes Metab J. 2026 Nov;50(6): 1021-1043
      Continuous glucose monitoring (CGM) has emerged as a promising approach to improving glycemic management in hospitalized individuals. Evidence from inpatient studies supports the benefits of CGM in monitoring glucose trends and improving the detection of otherwise unrecognized hypoglycemic and hyperglycemic episodes. Improvements in glycemic control have also been reported with CGM-integrated management, although these benefits may depend on structured insulin titration protocols, confirmatory point-of-care testing, dedicated glycemic management teams, and institutional workflows. However, the inpatient setting presents unique challenges, including hemodynamic instability, surgical interventions, radiologic procedures, and potential drug interference, which may affect CGM accuracy and safety. Systematic guidelines for implementing CGM in inpatient care remain scarce internationally, highlighting the need for structured evidence synthesis and practical recommendations. In this position statement, the Korean Diabetes Association Digital Health Committee reviews current evidence on the efficacy and accuracy of CGM in inpatient settings and highlights key considerations for its safe implementation, including target populations, hybrid monitoring strategies, and procedural safety. We propose an operational framework for inpatient CGM use, aiming to establish a foundation for its systematic adoption and to inform future institutional and regulatory frameworks.
    Keywords:  Clinical protocols; Continuous glucose monitoring; Electronic health records; Glycemic control; Hypoglycemia; Inpatients; Intensive care units
    DOI:  https://doi.org/10.4093/dmj.2026.0923
  9. Front Clin Diabetes Healthc. 2026 ;7 1953753
       Purpose: Continuous glucose monitoring (CGM) is increasingly studied beyond established diabetes, including prediabetes and other intermediate hyperglycemic states. This study mapped the scientific literature at this intersection and characterized publication patterns, collaboration, citation structure, and thematic organization.
    Methods: PubMed and Scopus were searched with a cutoff reported as May 20, 2026. After deduplication and title/abstract screening, 212 potentially eligible reports underwent full-text assessment; 176 publications met the final eligibility criteria. Descriptive and thematic analyses were conducted on the complete corpus. Citation- and reference-based indicators were calculated separately for the 169 included publications indexed in Scopus. Author Keywords were harmonized with a documented synonym dictionary before conceptual analyses.
    Results: The 176 included publications spanned 1994-2026, 95 sources, and 1,221 authors. Publication output increased markedly after 2020 and reached 44 publications in 2025; 2026 was incomplete at the search cutoff. The leading sources were Journal of Diabetes Science and Technology (n=22) and Diabetes Technology & Therapeutics (n=13). The most frequent harmonized Author Keywords were continuous glucose monitoring (n=90), prediabetes (n=67), diabetes (n=25), glycemic variability (n=23), and type 2 diabetes (n=21). The keyword co-occurrence network contained 46 connected terms in four clusters. In the Scopus subset, international co-authorship was 22.49%, and corresponding-author publications were led by the United States (n=63), Japan (n=15), China (n=10), and Germany (n=9).
    Conclusion: The literature on CGM and prediabetes has expanded substantially and is organized around a core linking CGM, prediabetes, glycemic variability, and related metabolic and digital-health topics. This bibliometric analysis maps research activity and evidence gaps; it does not establish the clinical effectiveness, preventive benefit, behavioral effectiveness, or cost-effectiveness of CGM in people with prediabetes.
    Keywords:  continuous glucose monitoring; digital health; glycemic variability; prediabetes; bibliometric analysis; thematic mapping
    DOI:  https://doi.org/10.3389/fcdhc.2026.1953753
  10. Diabetes Obes Metab. 2026 Nov 16.
      
    Keywords:  continuous glucose monitoring; glycaemic control; median absolute relative difference; sensor accuracy
    DOI:  https://doi.org/10.1111/dom.71537
  11. Hum Factors Health. 2026 Dec;10 100156
       Objective: We aimed to study the experience of using continuous glucose monitoring (CGM) among older Chinese Americans with cognitive impairment (CI) and their care partners. We also explored physicians' perspectives on using CGM in older adults with cognitive decline.
    Background: CI can heighten the challenges of managing type 2 diabetes (T2D), particularly among older Chinese Americans due to the interplays of cultural, financial, and health-related burdens and older adults with cognitive decline that add additional challenges of diabetes management. The application of CGM in such populations remains understudied.
    Method: Older Chinese American adults with CI and T2D and their care partners were recruited from the New York City (NYC) community. Clinicians who had clinical experience of the application of CGM in individuals with diabetes and cognitive decline were recruited nationally. After brief education, patients used CGM for 10 days and shared the data with their care partners. In-depth interviews were conducted among older Chinese Americans with both T2D and CI (n = 11), care partners (n = 11), and clinicians (n = 8), transcribed, and then thematically analyzed using ATLAS.ti software.
    Results: Older Chinese Americans with both T2D and CI had a mean age of 74.5 ± 5.2 years, and 63.6% were women. They reported CGM helped them assess the influence of various foods on glucose levels in order to choose appropriate foods (n = 10) and portion sizes (n = 5), gain insight on the role and impact of exercise (n = 5), enhance care partner involvement (n = 5) and communication (n = 4), and promote a positive mindset by improving management confidence or disease understanding (n = 9) in diabetes self-management. Care partners echoed similar sentiments but added that the device enhanced diabetes management as it was more persuasive in motivating behavioral changes (n = 5), and increased care partner involvement by allowing them to check in more often (n = 6) and review data with the patient at anytime and anywhere (n = 4). Clinicians emphasized that CGM provided real-time, shareable continuous data, in contrast with occasional A1C results (n = 5), improving safety, supporting individualized treatment decisions (n = 5), highlighting the importance of strong care partner support systems (n = 8), and noting that newer models with automatic data transmission (Dexcom G6/G7) are especially valuable (n = 5).
    Conclusion: Our findings indicate that CGM was feasible in easing management burden for older Chinese Americans with CI and T2D, while also enhancing care partner involvement and supporting clinicians in individualized treatment decisions.
    Application: Potential applications of this research include the adaptation of the CGM in older Chinese Americans with CI and T2D to better accommodate their cultural needs in diabetes management.
    Keywords:  Cognitive impairment; Continuous glucose monitoring; Diabetes mellitus; Mobile applications; Wearable electronic devices
    DOI:  https://doi.org/10.1016/j.hfh.2026.100156
  12. Diabetol Metab Syndr. 2026 Aug 27. pii: 261. [Epub ahead of print]18(1):
       BACKGROUND: Type 2 diabetes mellitus (T2DM) complicated by white matter hyperintensities (WMH) represents a high-risk population for cognitive decline. However, the association between continuous glucose monitoring (CGM) metrics and mild cognitive impairment (MCI) in this specific population remains inadequately explored. This study aimed to evaluate the associations between hemoglobin A1c (HbA1c), CGM metrics and MCI in patients with T2DM and WMH, and to identify potential threshold effects and subgroup differences.
    METHODS: This single-center cross-sectional study enrolled 1068 hospitalized patients with T2DM and WMH from January 2020 to December 2025. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), with MCI defined as a score of 18-25. Glycemic metrics included HbA1c and CGM-derived parameters, namely mean amplitude of glycemic excursions (MAGE), coefficient of variation (CV), time in range (TIR), time above range (TAR), time below range (TBR), and mean of daily differences (MODD). Multivariable logistic regression, restricted cubic splines, threshold effects analysis, ROC curves, and subgroup interaction tests were performed.
    RESULTS: Among 1068 patients (396 MCI, 672 non-MCI), MCI patients were older, had fewer years of education, more severe WMH, longer diabetes duration, and higher HbA1c (all P < 0.05). After multivariable adjustment, higher HbA1c (OR = 1.48), MAGE (OR = 3.1), CV (OR = 1.013), TBR (OR = 1.26), and lower TIR (OR = 0.92) were independently associated with MCI (all P < 0.05). MAGE showed the best discriminatory performance (AUC = 0.713). Nonlinear associations and significant threshold effects were identified: MCI risk increased significantly when MAGE ≥ 3.95 mmol/L (OR = 6.23) or HbA1c ≥ 7.86% (OR = 2.94), and decreased when TIR ≥ 65.0% (OR = 0.94). Subgroup analyses revealed effect modifications by alcohol consumption for CV and TIR, and by BMI for TBR. Additionally, MODD and TAR after full adjustment showed no independent associations.
    CONCLUSIONS: In this cross‑sectional study of patients with T2DM and WMH, higher MAGE, HbA1c, CV, and TBR, as well as lower TIR, were independently associated with MCI, with MAGE showing the best discriminative ability. Furthermore, the risk of MCI increased substantially when MAGE ≥ 3.95 mmol/L or HbA1c ≥ 7.86%, and decreased when TIR ≥ 65.0%. These above association warrant further validation in prospective studies before being considered as potential targets for cognitive preservation.
    Keywords:  Continuous glucose monitoring; Mild cognitive impairment; Type 2 diabetes mellitus; White matter hyperintensities
    DOI:  https://doi.org/10.1186/s13098-026-02287-w
  13. J Diabetes Sci Technol. 2026 Nov 19. 19322968261502745
       BACKGROUND: Automated insulin delivery (AID) improves glycemic outcomes in trials, but long-term real-world data on comprehensive continuous glucose monitoring (CGM) metrics remain limited in the Middle East.
    METHODS: We conducted a prospective observational cohort study of adults with type 1 diabetes mellitus (T1DM) initiating Control-IQ (CIQ) or MiniMed 780G (MMG) at King Fahad Medical City, Riyadh, Saudi Arabia, between December 2023 and November 2025. Participants were followed for 12 months. Continuous glucose monitoring outcomes included time in range (TIR: 70-180 mg/dL), time above range (TAR), time below range (TBR), glycemic management indicator (GMI), mean sensor glucose, and coefficient of variation (CV) and assessed at baseline and 6 post-initiation time points. Glycated hemoglobin A1c (HbA1c) was assessed using paired pre- and post-AID values.
    RESULTS: A total of 132 adults were included: 76 using CIQ and 56 using MMG. Mean age was 27.2 ± 7.7 years, 68.9% were female, and mean diabetes duration was 14.5 ± 7.9 years. Time in range increased from 59.0 ± 15.4% at baseline to 72.3 ± 10.2% at 2 weeks and remained sustained at 12 months (73.5 ± 11.5%; +15.1 percentage points; P < .001). Time below range <70 mg/dL decreased from 5.3 ± 5.3 to 1.4 ± 1.2%. Glycated hemoglobin A1c decreased from 7.42 ± 1.13 to 6.52 ± 0.73% (P < .001; n = 106). Time in range ≥70% increased from 29.0% to 71.0%, and HbA1c <7% increased from 30.3% to 74.5%. Severe hypoglycemia and diabetic ketoacidosis rates were significantly reduced.
    CONCLUSION: In a Saudi tertiary diabetes center, AID initiation was associated with rapid and sustained 12-month improvements in TIR, HbA1c, hypoglycemia exposure, and acute diabetes-related events.
    Keywords:  automated insulin delivery; closed-loop insulin delivery; continuous glucose monitoring; prospective real-world evidence; time in range; type 1 diabetes mellitus
    DOI:  https://doi.org/10.1177/19322968261502745
  14. Front Endocrinol (Lausanne). 2026 ;17 1991652
      Type 1 diabetes management in adolescents remains challenging due to physiological and behavioral factors. This review summarizes recent advances in three interconnected technologies: continuous glucose monitoring (CGM), automated insulin delivery (AID), and remote care. CGM provides real-time glycemic data with time in range (TIR) as the core metric, improving glycemic outcomes when implemented with structured education. AID systems, particularly hybrid closed-loop devices, consistently increase TIR, reduce glycated hemoglobin (HbA1c), and lower risks of severe hypoglycemia and diabetic ketoacidosis (DKA) across randomized trials and real-world studies, with validated efficacy in children as young as 1-year-old. Remote care models leverage continuous data streams to enable individualized follow-up, showing glycemic outcomes approaching those of traditional visits in comparative studies while improving access and psychosocial support. Despite proven benefits, barriers remain, including socioeconomic inequities in technology access, alarm fatigue, and implementation gaps across healthcare systems. Future priorities include fully closed-loop systems, dual-hormone approaches, algorithm optimization for exercise and illness, long-term psychosocial outcomes, and equitable implementation strategies. Clinical practice should integrate these technologies through multidisciplinary teams, early initiation, and patient-centered support to transform adolescent diabetes care from intermittent visits to continuous digital management.
    Keywords:  adolescents; automated insulin delivery; continuous glucose monitoring; hybrid closed-loop systems; telemedicine; type 1 diabetes
    DOI:  https://doi.org/10.3389/fendo.2026.1991652
  15. Diabetes Obes Metab. 2026 Nov 18.
       AIMS: Pre-pregnancy obesity substantially increases the risk of gestational diabetes mellitus (GDM), yet preventive strategies before routine GDM screening remain limited. The Glucose monitoring to Lower risk of GDM in Obese pregnant Women (GLOW) trial aims to determine whether continuous glucose monitoring (CGM) initiated in early pregnancy reduces the incidence of GDM in women with pre-pregnancy obesity.
    MATERIALS AND METHODS: GLOW is a national, multicentre, open-label, parallel-group randomised controlled trial enrolling 1034 women with pre-pregnancy body mass index ≥ 28 kg/m2, a singleton pregnancy and gestational age ≤ 14+6 weeks at eight hospitals in China. Participants will be randomised 1:1 to routine antenatal care alone or routine antenatal care plus CGM. In the CGM group, five consecutive 14-day sensors will be used from 14+0-14+6 to 24+0-24+6 weeks of gestation (70 days in total), with access to glucose values and standardised CGM education. The primary endpoint is the incidence of GDM diagnosed by a 75-g oral glucose tolerance test at 24+0-24+6 weeks. Secondary outcomes include gestational weight gain, maternal metabolic and anthropometric measures, lifestyle behaviours and maternal and neonatal outcomes.
    RESULTS AND CONCLUSIONS: GLOW will determine whether early CGM introduced before routine GDM screening can reduce GDM incidence and favourably influence maternal metabolic and pregnancy outcomes in women with pre-pregnancy obesity. The findings may inform the role of early CGM as a preventive strategy in this high-risk population.
    TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2600130043.
    Keywords:  continuous glucose monitoring; gestational diabetes mellitus; obesity; randomised controlled trial
    DOI:  https://doi.org/10.1111/dom.71563
  16. Forensic Sci Med Pathol. 2026 Nov 16.
      Diabetes mellitus is a common metabolic condition with significance in the forensic context due to the associated risk for fatal dysglycemic events. In all deaths of individuals with diabetes, careful inspection of diabetes management devices is advisable, as they may provide invaluable insights into the circumstances preceding death. This study investigated the prevalence of insulin pumps and Continuous Glucose Monitoring (CGM) devices in Finnish forensic autopsies during the past decade and assessed their utilization in the cause-of-death investigation. Data was retrospectively extracted from a national electronic platform containing all forensic autopsy records 2016-2025, using predefined keyword searches targeted at diabetes, insulin pumps, and CGM devices. Cases were manually reviewed. We found records of 37 autopsied insulin pump cases (median age 41 years (range 18-72); 3.4% of all autopsied type 1 diabetics). Documentation about the insulin delivery system was variable. Cannula fixation was noted in 32.3% and pump history in 32.4% of the cases. The proportion of CGM-associated autopsies among all diabetic autopsies increased from 0.1% in 2016 to 4.1% in 2025, with a total of 352 autopsied CGM cases during the study period (median age 61 years (range 15-94)). CGM data was utilized in 9.1% of the associated cause-of-death investigations. Our findings suggest non-systematic examination of insulin pumps and CGM data in current Finnish forensic cause-of-death investigation practices. Education and standardized protocols for insulin pump examination and CGM data review are recommended to ensure quality and reliability in diabetes-related forensic cause-of-death investigations.
    Keywords:  Autopsy; CGM; Continuous glucose monitoring; Diabetes; Forensic pathology; Insulin pump
    DOI:  https://doi.org/10.1007/s12024-026-01395-3
  17. Front Endocrinol (Lausanne). 2026 ;17 1970132
       Objective: The coefficient of variation (CV) of glycemia, calculated from continuous glucose monitoring (CGM) data, quantifies intraday glycemic variability. However, its association with reduced appendicular skeletal muscle mass in patients with type 2 diabetes mellitus (T2DM) remains unclear. This study aimed to investigate the association between glycemic CV and reduced ASMI.
    Methods: This retrospective cross-sectional study enrolled 1453 hospitalized T2DM patients aged ≥18 years who required intensive insulin pump therapy. Baseline clinical and laboratory data were collected, and glycemic CV was computed from CGM records. ASMI was measured using bioelectrical impedance analysis. Participants were categorized into the reduced ASMI group (n = 341) and normal muscle mass group (n = 1112) according to ASMI values, and further stratified by quartiles of glycemic CV. Multivariable logistic regression was performed to examine the independent association between glycemic CV and reduced ASMI. Restricted cubic spline (RCS) models were constructed to characterize the shape of this association. Subgroup analyses and multiple sensitivity analyses were conducted to verify the robustness of findings.
    Results: Glycemic CV was significantly higher in participants with reduced ASMI. In the fully adjusted multivariable model, elevated glycemic CV was independently associated with increased odds of reduced ASMI (OR = 1.17, 95% CI: 1.04-1.31, P = 0.008). RCS analysis indicated a statistically significant overall association, with no statistically significant nonlinearity (P = 0.148). Subgroup analyses revealed no significant interactions across strata of age, diabetes duration, gender, HbA1c, and visceral fat area. Sensitivity analysis demonstrated that the association between glycemic CV and reduced ASMI disappeared after additional adjustment for BMI (OR = 0.96, 95% CI: 0.52-1.82, P = 0.902), suggesting that the association was sensitive to adjustment for BMI.
    Conclusions: In hospitalized patients with type 2 diabetes receiving intensive insulin pump therapy, elevated glycemic variability was associated with reduced ASMI in the primary model; however, this association was no longer statistically significant after additional adjustment for BMI, indicating that the association was sensitive to adjustment for BMI. Intra-day glycemic variability may provide clues for exploring the mechanisms underlying skeletal muscle mass maintenance in this population.
    Keywords:  bioelectrical impedance analysis; coefficient of glycemic variation; continuous glucose monitoring system; reduced appendicular skeletal muscle mass index; type 2 diabetes mellitus
    DOI:  https://doi.org/10.3389/fendo.2026.1970132
  18. Respir Med. 2026 Nov 16. pii: S0954-6111(26)00667-0. [Epub ahead of print]265 109298
       BACKGROUND: Children with cystic fibrosis (CF) experience chronic inflammation and early glucose abnormalities. Whether dietary inflammatory potential is associated with glycemic outcomes in pediatric CF remains unclear.
    OBJECTIVE: To examine associations of the Dietary Inflammatory Index (DII) with continuous glucose monitoring (CGM) metrics and systemic inflammatory markers in children with CF.
    METHODS: This exploratory cross-sectional study included 24 clinically stable children with CF aged 6-18 years who were not receiving CFTR modulator therapy. DII scores were calculated from three non-consecutive 24-h dietary recalls. CGM-derived outcomes included mean glucose, time in range (TIR), time above range (TAR), glucose variability, and glucose management indicator (GMI). Inflammatory markers were measured using ELISA. Associations were examined using multivariable regression adjusted for age and sex.
    RESULTS: After adjustment for age and sex, higher DII scores were associated with higher mean glucose (β = 0.512, p = 0.021), GMI (β = 0.583, p = 0.011), and TAR (β = 0.466, p = 0.044). The inverse association with TIR was not statistically significant (β = -0.421, p = 0.070). DII was also positively associated with log-CRP (β = 0.528, p = 0.037), whereas other inflammatory markers were not significantly associated with DII.
    CONCLUSION: Higher dietary inflammatory potential was associated with greater glycemic exposure and CRP in children with CF. These exploratory findings warrant confirmation in larger longitudinal studies, including CFTR modulator-treated cohorts.
    Keywords:  Continuous glucose monitoring; Cystic fibrosis; Cystic fibrosis related diabetes; Dietary inflammatory index; Inflammatory diet
    DOI:  https://doi.org/10.1016/j.rmed.2026.109298
  19. Clin Geriatr Med. 2027 Feb;pii: S0749-0690(26)00043-1. [Epub ahead of print]43(1): 55-66
      Improved survival has produced a rapidly growing population of older adults living with type 1 diabetes, a group whose care needs differ substantially from those of younger patients. Age-related changes in renal function, body composition, and counter-regulatory hormone responses, together with geriatric syndromes such as frailty, cognitive impairment, and functional decline, heighten hypoglycemia risk and complicate self-management. This article reviews the epidemiology, clinical challenges, individualized glycemic targets and monitoring, chronic complications and screening, and diabetes technology in this population. It emphasizes hypoglycemia prevention, comprehensive functional and social assessment, and the integration of geriatric principles into patient-centered type 1 diabetes care.
    Keywords:  Continuous glucose monitoring; Hypoglycemia; Individualized glycemic targets; Older adults; Type 1 diabetes
    DOI:  https://doi.org/10.1016/j.cger.2026.08.010
  20. Cureus. 2026 Oct;18(10): e117889
      Artificial intelligence (AI) is increasingly being investigated for glucose prediction and personalized glycemic management in diabetes, particularly through continuous glucose monitoring and multimodal patient data. However, strong predictive performance does not necessarily translate into clinically meaningful benefit. This systematic review evaluated the predictive performance and clinical outcomes of AI-based approaches for glucose prediction, prediction of glycemic events, and AI-enabled glycemic management in adults with diabetes mellitus. A systematic literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, the Cochrane Library, and Google Scholar from database inception through July 2026. Studies evaluating AI or machine-learning approaches for glucose prediction, prediction of hypoglycemia or hyperglycemia, or AI-enabled glycemic management were included. Data on study characteristics, diabetes type, AI architecture, input variables, prediction targets and horizons, validation strategies, predictive performance measures, clinical outcomes, and methodological quality were extracted. Risk of bias was assessed using design-appropriate validated tools. Thirty studies were included, comprising evidence from type 1 diabetes, type 2 diabetes, and mixed diabetes populations. Most studies investigated short-term glucose forecasting or hypoglycemia prediction, with prediction horizons ranging from approximately 15 minutes to 24 hours. Reported predictive performance was generally promising, although substantial heterogeneity in datasets, model architectures, prediction horizons, outcome definitions, and validation strategies limited direct comparisons. Increasingly, models incorporated insulin, meals, physical activity, demographic characteristics, and other clinical variables to support personalized and multimodal prediction. However, clinical evidence was considerably more limited than technical predictive evidence, with relatively few studies evaluating prospective clinical or decision-support interventions and clinically meaningful outcomes such as time in range or HbA1c. Overall, AI-based approaches demonstrated promising performance for glucose and glycemic event prediction, with a growing emphasis on personalized and multimodal modeling, but evidence for clinical effectiveness remains limited. Stronger prospective, externally validated, and randomized studies using standardized, clinically meaningful outcomes are needed to establish the clinical effectiveness, generalizability, and implementation of AI-based approaches in routine diabetes care.
    Keywords:  artificial intelligence; continuous glucose monitoring; diabetes mellitus; glucose prediction; glycemic management; type 1 diabetes; type 2 diabetes
    DOI:  https://doi.org/10.7759/cureus.117889
  21. Clin Geriatr Med. 2027 Feb;pii: S0749-0690(26)00044-3. [Epub ahead of print]43(1): 67-79
      Diabetes technology offers new opportunities to improve glycemic control and quality of life for older adults living with diabetes. Devices such as continuous glucose monitors, automated insulin delivery systems, and smart insulin pens can enhance treatment precision and decrease the burden of diabetes self-management. Age-related changes in cognition and functional status can affect older adults' ability to safely and competently operate these complex devices. In addition, older adults may face significant barriers related to digital literacy, technology-related anxiety, and social factors, including caregiver support. Individualized assessment is essential when selecting appropriate technologies for older adult patients.
    Keywords:  Diabetes medical devices; Diabetes technology; Older adults; Technology challenges and limitations
    DOI:  https://doi.org/10.1016/j.cger.2026.08.011